Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | GRK5 | P34947 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | NEK4 | P51957 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924677 | 0.84 | PDE5A (0.43) | EPAS1ABCG2MEN1KMT2AEGFR | |
| SCHEMBL923315 | 0.84 | PDE5A (0.41) | EPAS1ABCG2MEN1KMT2AEGFR | |
| SCHEMBL923415 | 0.84 | EPAS1 (0.49) | EPAS1ABCG2KDREGFRABCB1 | |
| SCHEMBL923119 | 0.84 | MAPT (0.44) | ABCG2MEN1KMT2AKDRDYRK3 | |
| SCHEMBL923231 | 0.80 | MKNK1 (0.67) | EGFRRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12903928 | 0.69 | ELANE (0.36) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL20712211 | 0.68 | IDO1 (0.64) | EPAS1IDO1ABCG2MEN1KMT2A | |
| SCHEMBL7179082 | 0.68 | PDE5A (0.44) | PDE5A | |
| SCHEMBL6766837 | 0.67 | MAPK1 (0.38) | MEN1KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL6743866 | 0.67 | MAPK1 (0.38) | MEN1KMT2ARAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | claimed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | claimed |
| EP-2257554-A1 | TRICYCLIC BENZOÝ4,5¨THIENO-Ý2,3-D¨PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Vichem Chemie Kutató KFT (HU) | 2010-12-08 | — | — | EP | claimed |
| WO-2009104026-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATÓ KFT (HU) | 2009-08-27 | — | — | WO | claimed |
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | disclosed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | TYMS, TYMP, DPYD | EPAS1 3624/4885IDO1 1293/4885ABCG2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.